Market Cap 465.20B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 25.83
Forward PE 18.61
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 6,406,600
Avg Vol 7,045,160
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 34%
Beta 0.30
Analysts Strong Sell
Price Target $265.79

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Olivia_Strickland
Olivia_Strickland Jul. 31 at 12:52 PM
$ABBV got the EU approval headline overnight but premarket's down 5.6% at 248.20, tape feels heavy. Q2 earnings looming and someone's de-risking ahead of it. what level you guys watching here live premarket tape: https://tapeboard.com/go/st/research/ABBV?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=abbv-pm-dn-tape&utm_term=research
0 · Reply
HydrogenH2
HydrogenH2 Jul. 31 at 12:40 PM
$ABBV Better entry point @ $225 !!
0 · Reply
fxshea
fxshea Jul. 31 at 12:36 PM
$ABBV Profit taking?
0 · Reply
shoagh12
shoagh12 Jul. 31 at 12:08 PM
$ABBV we wil change to Green Today Top Results
0 · Reply
grnstock
grnstock Jul. 31 at 12:02 PM
$ABBV I do not understand where 14 cents in the headline come from. Should it be 4 cents! GL
0 · Reply
profit_guru
profit_guru Jul. 31 at 11:59 AM
$ABBV - P/E too high…should be below 230 looks like its blockbuster drugs are showing slowdown…guidance weak
0 · Reply
grnstock
grnstock Jul. 31 at 11:58 AM
$ABBV great Q2 earnings, updated 2026 adj. eps guidance from $13.91 - $14.11 to $ $13.87 -$14.07 on Apogee buy. GL
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 31 at 11:56 AM
$ABBV Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $2.03 up 290.38% YoY • Reported revenue of $16.99B up 10.16% YoY • AbbVie is updating its 2026 adjusted diluted EPS guidance range from $13.91 - $14.11 to $13.87 - $14.07, reflecting an anticipated $0.14 dilutive impact from the proposed acquisition of Apogee Therapeutics.
0 · Reply
LiveSquawk
LiveSquawk Jul. 31 at 11:54 AM
$ABBV AbbVie Q2 2026 Earnings - Adj EPS $3.65 (est $3.61) - Net Rev. $16.99B (est $16.77B) - Skyrizi Rev $5.51B (est $5.43B) - RINVOQ Rev. $2.53B (est $2.48B) - Humira Rev $756M (est $734.1M) - Imbruvica $532M (est $563.2M) - Sees FY Adj EPS $13.87 To $14.07, Saw $13.91 To $14.11 - Yr View Incl Unfavourable Impact Of $0.58/SHR ON IPR&D - Yr View Incl $0.14/SHR Dilutive Impact On Apogee Deal
0 · Reply
theoptionsplug
theoptionsplug Jul. 31 at 4:17 AM
THINGS TO WATCH, FRIDAY, 7/31/2026 👁️ $CVX $XOM $MRNA $ABBV $SPY
0 · Reply
Latest News on ABBV
AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - Just now

AbbVie Earnings release: Q2 2026


AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

Jul 31, 2026, 8:36 AM EDT - 19 minutes ago

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps


AbbVie reports Q2 adjusted EPS $3.65, consensus $3.61

2026-07-31T11:51:57.000Z - 1 hour ago

AbbVie reports Q2 adjusted EPS $3.65, consensus $3.61


AbbVie Reports Second-Quarter 2026 Financial Results

Jul 31, 2026, 7:47 AM EDT - 1 hour ago

AbbVie Reports Second-Quarter 2026 Financial Results


JUVÉDERM® Day Returns to U.S. on August 19

Jul 30, 2026, 8:00 AM EDT - 1 day ago

JUVÉDERM® Day Returns to U.S. on August 19


AbbVie announces Elahere availability in Singapore

2026-07-29T09:30:43.000Z - 2 days ago

AbbVie announces Elahere availability in Singapore


AbbVie announces European Commission approval for Rinvoq

2026-07-29T09:15:30.000Z - 2 days ago

AbbVie announces European Commission approval for Rinvoq


AbbVie price target raised to $300 from $275 at Barclays

2026-07-29T09:10:59.000Z - 2 days ago

AbbVie price target raised to $300 from $275 at Barclays


AbbVie price target raised to $282 from $273 at Canaccord

2026-07-22T10:40:12.000Z - 9 days ago

AbbVie price target raised to $282 from $273 at Canaccord


AbbVie price target raised to $260 from $230 at Citi

2026-07-15T10:21:06.000Z - 16 days ago

AbbVie price target raised to $260 from $230 at Citi


AbbVie price target raised to $260 from $230 at UBS

2026-07-13T16:30:09.000Z - 17 days ago

AbbVie price target raised to $260 from $230 at UBS


AbbVie price target raised to $300 from $258 at BMO Capital

2026-07-13T12:27:09.000Z - 18 days ago

AbbVie price target raised to $300 from $258 at BMO Capital


AbbVie price target raised to $280 from $260 at RBC Capital

2026-07-10T13:10:21.000Z - 20 days ago

AbbVie price target raised to $280 from $260 at RBC Capital


AbbVie price target raised to $276 from $234 at BofA

2026-07-10T10:31:16.000Z - 21 days ago

AbbVie price target raised to $276 from $234 at BofA


AbbVie price target raised to $295 from $260 at Wells Fargo

2026-07-10T10:20:22.000Z - 21 days ago

AbbVie price target raised to $295 from $260 at Wells Fargo


AbbVie price target raised to $280 from $260 at JPMorgan

2026-07-09T12:06:14.000Z - 22 days ago

AbbVie price target raised to $280 from $260 at JPMorgan


AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 5 weeks ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 5 weeks ago

AbbVie's $11 Billion Immunology Bet

APGE


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 5 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 5 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 5 weeks ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 6 weeks ago

AbbVie Declares Quarterly Dividend


US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 2 months ago

US FDA approves AbbVie's rare blood cancer drug


AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 2 months ago

AbbVie Transcript: AGM 2026


Olivia_Strickland
Olivia_Strickland Jul. 31 at 12:52 PM
$ABBV got the EU approval headline overnight but premarket's down 5.6% at 248.20, tape feels heavy. Q2 earnings looming and someone's de-risking ahead of it. what level you guys watching here live premarket tape: https://tapeboard.com/go/st/research/ABBV?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=abbv-pm-dn-tape&utm_term=research
0 · Reply
HydrogenH2
HydrogenH2 Jul. 31 at 12:40 PM
$ABBV Better entry point @ $225 !!
0 · Reply
fxshea
fxshea Jul. 31 at 12:36 PM
$ABBV Profit taking?
0 · Reply
shoagh12
shoagh12 Jul. 31 at 12:08 PM
$ABBV we wil change to Green Today Top Results
0 · Reply
grnstock
grnstock Jul. 31 at 12:02 PM
$ABBV I do not understand where 14 cents in the headline come from. Should it be 4 cents! GL
0 · Reply
profit_guru
profit_guru Jul. 31 at 11:59 AM
$ABBV - P/E too high…should be below 230 looks like its blockbuster drugs are showing slowdown…guidance weak
0 · Reply
grnstock
grnstock Jul. 31 at 11:58 AM
$ABBV great Q2 earnings, updated 2026 adj. eps guidance from $13.91 - $14.11 to $ $13.87 -$14.07 on Apogee buy. GL
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 31 at 11:56 AM
$ABBV Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $2.03 up 290.38% YoY • Reported revenue of $16.99B up 10.16% YoY • AbbVie is updating its 2026 adjusted diluted EPS guidance range from $13.91 - $14.11 to $13.87 - $14.07, reflecting an anticipated $0.14 dilutive impact from the proposed acquisition of Apogee Therapeutics.
0 · Reply
LiveSquawk
LiveSquawk Jul. 31 at 11:54 AM
$ABBV AbbVie Q2 2026 Earnings - Adj EPS $3.65 (est $3.61) - Net Rev. $16.99B (est $16.77B) - Skyrizi Rev $5.51B (est $5.43B) - RINVOQ Rev. $2.53B (est $2.48B) - Humira Rev $756M (est $734.1M) - Imbruvica $532M (est $563.2M) - Sees FY Adj EPS $13.87 To $14.07, Saw $13.91 To $14.11 - Yr View Incl Unfavourable Impact Of $0.58/SHR ON IPR&D - Yr View Incl $0.14/SHR Dilutive Impact On Apogee Deal
0 · Reply
theoptionsplug
theoptionsplug Jul. 31 at 4:17 AM
THINGS TO WATCH, FRIDAY, 7/31/2026 👁️ $CVX $XOM $MRNA $ABBV $SPY
0 · Reply
parcha
parcha Jul. 31 at 3:08 AM
Friday's big stock stories: What’s likely to move the market in the next trading session $ABBV AbbVie earnings The biotech reports Friday on “Squawk Box” also. AbbVie is up 22% since last reporting. Shares hit a high Wednesday, before falling back a bit. https://www.cnbc.com/2026/07/30/fridays-big-stock-stories-whats-likely-to-move-the-market-in-the-next-trading-session.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
TNNStockAnalysisNews
TNNStockAnalysisNews Jul. 31 at 2:30 AM
Top Stocks to Watch Tomorrow — July 31, 2026 $XOM -- Reports Before Market Open $ABBV -- Reports $MRNA -- Reports $D -- Reports $FTS -- Reports https://truthsandnews.com/markets/top-10-stocks-to-watch-tomorrow-july-31-2026-exxon-cboe
0 · Reply
Spud14
Spud14 Jul. 31 at 1:16 AM
$ABBV check out the pitching mound at the Thursday night Braves- Nationals game
1 · Reply
Spud14
Spud14 Jul. 31 at 12:53 AM
$ABBV skyrizi is well-established and receives a ton of exposure from all of the TV ads
0 · Reply
profit_guru
profit_guru Jul. 31 at 12:33 AM
$ABBV - most popular drug skyrizi will have new competition from $JNJ FDA approved icotyde
1 · Reply
clan
clan Jul. 30 at 10:33 PM
$JNJ $ABBV $GSK If you know Dry Powder Inhalation (DPI), you know it's great for all Mannkind. 🚫💉
0 · Reply
Oldpuck
Oldpuck Jul. 30 at 8:21 PM
$ABBV not the way you like to head into earnings
1 · Reply
judgeyoung2
judgeyoung2 Jul. 30 at 7:55 PM
$ABBV @cubie thoughts on the far otm far dated puts ?
0 · Reply
profit_guru
profit_guru Jul. 30 at 7:52 PM
$ABBV - if they miss earnings it will open beliw 230…imo
0 · Reply
ra1980
ra1980 Jul. 30 at 7:51 PM
$UNH $ELV $ABBV $MCK $MDLN if the tech sector rises again it will be good idea to short health sector
1 · Reply
DidYouReadThis
DidYouReadThis Jul. 30 at 7:50 PM
$OTLK Do you know what a #14d9 is? Do you think there could possibly be one within 2 weeks-20 years? ​$NVS $ABBV $REGN
0 · Reply
ra1980
ra1980 Jul. 30 at 7:43 PM
$ABBV short some here🤢🤢🤢 Hope no fuck tomorrow
0 · Reply